

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**Date of Report: 08/31/2022**

**Commission File Number: 001-39777**

**Nanobiotix S.A.**  
(Exact Name of Registrant as Specified in its Charter)

**60 Rue de Wattignies  
75012 Paris, France  
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**EXHIBIT INDEX**

**Exhibit      Title**

[99.1](#)            [Press Release, dated August, 31, 2022](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**NANOBIOTIX S.A.**  
(Registrant)

08/31/2022

By: /s/ Bart Van Rhijn  
Bart Van Rhijn  
Chief Financial Officer

## Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 31, 2022--Regulatory News:

NANOBIOTIX (Euronext : NANO — NASDAQ: NBTX – the “**Company**”) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference to take place in-person in New York and virtually September 12<sup>th</sup>-14<sup>th</sup> 2022.

Details for the presentation are as follow:

Date: Monday, September 12, 2022  
Time: 2:00 – 2:30 PM Eastern Time

A live webcast of the presentation will be available on the events page of the Investors section of the Company’s website. A replay will be available on the Nanobiotix website within 48 hours of the event. The Company’s corporate presentation can be downloaded [here](#).

To request a one-on-one in-person or virtual meeting, please register [here](#).

\*\*\*

### About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The Company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The Company’s resources are primarily devoted to the development of its lead product candidate– NBTXR3 —which is the product of its proprietary oncology platform .

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on LinkedIn and Twitter.

## Contacts

*Nanobiotix*

### Communications Department

*Brandon Owens*  
*VP, Communications*  
+1 (617) 852-4835  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

### Investor Relations Department

*Kate McNeil*  
*SVP, Investor Relations*  
+1 (609) 678-7388  
[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

*Media Relations*

### FR – Ulysse Communication

*Pierre-Louis Germain*  
+ 33 (0) 6 64 79 97 51  
[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)

### Global – LifeSci Advisors

*Ligia Vela-Reid*  
+44 (0) 7413825310  
[Lvela-reid@lifesciadvisors.com](mailto:Lvela-reid@lifesciadvisors.com)